Patents by Inventor David Bettoun

David Bettoun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220378869
    Abstract: The present disclosure provides a method for treatment of a subject suffering from Leigh Syndrome French Canadian Type (LSFC), the method comprising administering to the subject a therapeutically effective amount of a frataxin (FXN) therapeutic compound.
    Type: Application
    Filed: July 17, 2020
    Publication date: December 1, 2022
    Inventor: Joan David Bettoun
  • Publication number: 20220276258
    Abstract: The present disclosure provides methods for determining the amount of FXN or FXN fusion protein in a sample, e.g, a tissue sample, by using mass spectrometry.
    Type: Application
    Filed: July 29, 2020
    Publication date: September 1, 2022
    Inventors: Joan David Bettoun, Erik Johan Wagner, Xin Xu, Jean-Nicholas Mess, Amy Qiu Wang
  • Publication number: 20210363205
    Abstract: The present disclosure provides methods for treating or ameliorating a myelin associated disease or a mitochondria associated disease that comprising administering to a subject in need thereof a frataxin replacement therapeutic compound, e.g., a fusion protein comprising frataxin.
    Type: Application
    Filed: April 30, 2021
    Publication date: November 25, 2021
    Inventor: Joan David Bettoun
  • Publication number: 20210355177
    Abstract: The present disclosure provides a fusion protein useful for treating a non-nuclear organelle associated disorder, such as a genetic disorder, e.g., Friedrich's Ataxia. The fusion protein may comprise a protein of interest to be delivered to a non-nuclear organelle; an organelle targeting sequence (OTS); a cell penetrating peptide (CPP); and a target enhancing sequence (TES); wherein the CPP is capable of interference with delivery of the protein of interest to the non-nuclear organelle; and wherein the TES prevents said interference by the CPP. The fusion protein may also comprise a protein of interest to be delivered to a non-nuclear organelle; a CPP and a TES. The present disclosure also provides methods for treating a non-nuclear organelle associated disorder by administering the fusion protein to a subject in need thereof.
    Type: Application
    Filed: March 26, 2021
    Publication date: November 18, 2021
    Inventors: Joan David Bettoun, Rebecca Wissner
  • Publication number: 20210156874
    Abstract: The present disclosure provides methods, compositions and kits for measuring activity of a frataxin (FXN) protein, e.g., an FXN fusion protein. The present invention also provides methods for identifying compounds capable of modulating activity of an FXN protein, e.g., an FXN fusion protein.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 27, 2021
    Inventor: Joan David Bettoun
  • Patent number: 10954194
    Abstract: The invention relates to a method of treating a subject who has cancer or a non-malignant tumor, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: March 23, 2021
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20200377951
    Abstract: The present disclosure is based, at least in part, on providing a set of markers, also referred to herein as FXN-sensitive genomic markers (or FSGMs), the respective expression levels of which are positively or negatively correlated to frataxin (FXN) levels in a cell. Therefore, these FSGMs can be used to determine, evaluate, and/or monitor the effectiveness of FXN replacement therapy in a subject.
    Type: Application
    Filed: April 30, 2020
    Publication date: December 3, 2020
    Inventor: Joan David Bettoun
  • Patent number: 10752591
    Abstract: The invention relates to a method of inhibiting loss of muscle mass or muscle function in a subject in need thereof, or a method of treating miofibers ex vivo, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject or to the miofibers.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 25, 2020
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20190389806
    Abstract: The invention relates to a method of inhibiting loss of muscle mass or muscle function in a subject in need thereof, or a method of treating miofibers ex vivo, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject or to the miofibers.
    Type: Application
    Filed: July 3, 2019
    Publication date: December 26, 2019
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20190389805
    Abstract: The invention relates to a method of treating a subject who has cancer or a non-malignant tumor, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject.
    Type: Application
    Filed: July 3, 2019
    Publication date: December 26, 2019
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Patent number: 10377715
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 13, 2019
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20180362467
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Application
    Filed: December 6, 2017
    Publication date: December 20, 2018
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20170114019
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Application
    Filed: June 4, 2015
    Publication date: April 27, 2017
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20090117046
    Abstract: The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods of diagnosing and assessing predisposition to chronic inflammatory diseases. The present invention further provides methods for testing agents for effectiveness in treating and/or preventing diseases associated with chronic inflammatory or autoimmune conditions.
    Type: Application
    Filed: January 12, 2009
    Publication date: May 7, 2009
    Inventors: Yoram GRONER, David Bettoun
  • Publication number: 20060264393
    Abstract: The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods for treating T cell-related inflammatory conditions by cell therapy, gene therapy or antisense for up regulating or down regulating RUNX3. The invention further relates to methods of diagnosing and assessing predisposition to chronic inflammatory diseases. The present invention further provides methods for testing agents for effectiveness in treating and/or preventing diseases associated with chronic inflammatory or autoimmune conditions.
    Type: Application
    Filed: December 30, 2003
    Publication date: November 23, 2006
    Inventors: Yoram Groner, David Bettoun